Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy, Hormone.

Princess Margaret Cancer Center, Toronto, ON, Canada.

Survival: monthsCountry:Canada
Toxiciy Grade:5City/State/Province:Toronto, ON
Treatments:Chemotherapy, HormoneHospital:Princess Margaret Cancer Center
Drugs:Journal:Link
Date:Jul 2013

Description:

Patients:
This phase 3 study involved metastatic castration-resistant prostate cancer patients who had not received prior chemotherapy and who were divided into two separate treatment groups. Each group consisted of 612 patients; no median age information was provided.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel, the steroid prednisone (anti-inflammatory), and the biologic therapy agent aflibercept (growth factor receptor inhibitor that interferes with tumor blood supply).

Group B patients were treated with docetaxel, prednisone, and a placebo.

Toxicities:
Treatment-related deaths due to infection, heart attack, respiratory problems, and gastrointestinal bleeding were reported for group A. Grade 3-4 diarrhea and nausea/vomiting were also reported.

In group B, treatment-related deaths due to infection, heart attack, respiratory problems, and gastrointestinal bleeding were reported. Grade 3-4 diarrhea, vascular disorders, and fatigue were also reported.

Results:
The median overall survival times for groups A and B were 22.1 and 21.2 months, respectively.

Support:
This study was supported by Sanofi and Regeneron.

Correspondence: Dr. Ian Tannock; email: [email protected]



Back